Oral S-1 and carboplatin plus bevacizumab with maintenance S-1 and bevacizumab for chemo-naive patients (Pts) with advanced non-squamous non-small cell lung cancer (NSCLC).

Hiroyasu Kaneda,Yoshiko Urata,Isamu Okamoto,Yoshihiro Hattori,Keiko Okuno,Temiko Shimada,Masayuki Takeda,Takayasu Kurata,Masaki Miyazaki,M. Terashima,Kaoru Tanaka,Hidemi Kiyota,Hidetoshi Hayashi,Toshihiro Kudo,Takafumi Okabe,Koichi Azuma,Satoshi Morita,Kazuhiko Nakagawa,Shunichi Negoro,Miyako Satouchi

Oral S-1 and carboplatin plus bevacizumab with maintenance S-1 and bevacizumab for chemo-naive patients (Pts) with advanced non-squamous non-small cell lung cancer (NSCLC).

2012

e18060 Background: Our previous phase III trial has demonstrated that S-1 in combination with carboplatin has promising activity as well as superior toxicity profile compared with carboplatin/pacli...

Keywords:

Carboplatin
Squamous non-small cell lung cancer
Bevacizumab
Internal medicine
Oncology
Medicine
toxicity profile
non squamous
non-small cell lung cancer (NSCLC)
therapy naive

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations